Shareholder Alert: The Ademi Firm investigates whether Avidity Biosciences Inc. is obtaining a Fair Price for its Public Shareholders

MILWAUKEE, Oct. 28, 2025 /PRNewswire/ -- The Ademi Firm is investigating Avidity (Nasdaq: RNA) for possible breaches of fiduciary duty and other violations of law in its transaction with Novartis.

Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995.  There is no cost or obligation to you.

In the transaction, Avidity shareholders will receive $72.00 per share, valuing Avidity at approximately $12 billion on a fully diluted basis.

Avidity insiders will continue to receive substantial benefits as part of change of control arrangements.

The transaction agreement unreasonably limits competing transactions for Avidity by imposing a significant penalty if Avidity accepts a competing bid. We are investigating the conduct of the Avidity board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts

Ademi & Fruchter LLP                                 
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001

View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-alert-the-ademi-firm-investigates-whether-avidity-biosciences-inc-is-obtaining-a-fair-price-for-its-public-shareholders-302594855.html

SOURCE Ademi LLP